Alpelisib Pill

DRUG2 trials

Sponsors

GOG Foundation, Tianjin Medical University Second Hospital

Conditions

Endometroid Endometrial CancerPrecision MedicineSolid Tumor

Phase 2

A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer

Active, not recruitingNCT05154487

GOG FoundationEndometroid Endometrial Cancer

Start: 2024-09-11End: 2028-11-01Target: 51Updated: 2026-03-03

Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion

RecruitingNCT06739395

Tianjin Medical University Second HospitalPrecision Medicine, Solid Tumor

Start: 2024-11-01End: 2027-05-01Target: 300Updated: 2024-12-18

Related Papers

GOG3069: Phase 2 study of alpelisib and fulvestrant for PIK3CA-mutated estrogen receptor (ER)-positive endometrioid endometrial cancers.

Journal of Clinical Oncology2024-06-01